These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8771175)

  • 1. Effects of mazindol in two patients with Prader-Willi syndrome.
    Itoh M; Koeda T; Ohno K; Takeshita K
    Pediatr Neurol; 1995 Nov; 13(4):349-51. PubMed ID: 8771175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of Prader-Willi syndrome with long-term mazindol treatment.
    Inui A; Uemoto M; Takamiya S; Shibuya Y; Baba S; Kasuga M
    Arch Intern Med; 1997 Feb; 157(4):464. PubMed ID: 9046903
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical studies with mazindol.
    Inoue S
    Obes Res; 1995 Nov; 3 Suppl 4():549S-552S. PubMed ID: 8697057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate effectiveness in Prader-Willi syndrome.
    Smathers SA; Wilson JG; Nigro MA
    Pediatr Neurol; 2003 Feb; 28(2):130-3. PubMed ID: 12699864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological adaptation after a 12-week physical activity program for patients with Prader-Willi syndrome: two case reports.
    Amaro AS; Teixeira MC; de Mesquita ML; Rodrigues GM; Rubin DA; Carreiro LR
    J Med Case Rep; 2016 Jun; 10(1):181. PubMed ID: 27339289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of fluoxetine in an adolescent with Prader-Willi syndrome.
    Dech B; Budow L
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):298-302. PubMed ID: 2016235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychopharmacogenetic aspects of Prader-Willi syndrome.
    Tu JB; Hartridge C; Izawa J
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1137-40. PubMed ID: 1429418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy.
    Nishikawa T; Iizuka T; Omura M; Kuramoto N; Miki T; Ito H; Chiba S
    Endocr J; 1996 Dec; 43(6):671-7. PubMed ID: 9075607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone and fluoxetine in Prader-Willi syndrome.
    Benjamin E; Buot-Smith T
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):870-3. PubMed ID: 8340312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mazindol].
    Mori Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():683-6. PubMed ID: 21766681
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of obesity in Prader-Willi syndrome.
    Butler MG
    Nat Clin Pract Endocrinol Metab; 2006 Nov; 2(11):592-3. PubMed ID: 17082801
    [No Abstract]   [Full Text] [Related]  

  • 14. [The probable anorexigenic effect of naloxone in the Prader-Labhart-Willi syndrome].
    Mascherpa G; Cogliati F; Mauri R; Resentini M
    Minerva Pediatr; 1982 Aug 15-31; 34(15-16):675. PubMed ID: 7121431
    [No Abstract]   [Full Text] [Related]  

  • 15. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
    Selikowitz M; Sunman J; Pendergast A; Wright S
    Arch Dis Child; 1990 Jan; 65(1):112-4. PubMed ID: 2405783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mazindol administration improved hyperphagia after surgery for craniopharyngioma--case report.
    Sadatomo T; Sakoda K; Yamanaka M; Kutsuna M; Kurisu K
    Neurol Med Chir (Tokyo); 2001 Apr; 41(4):210-2. PubMed ID: 11381681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Self-induced cutaneous lesions in Prader-Willi syndrome].
    Plantin P; Milochau P; Broussine L; Blondin G
    Ann Dermatol Venereol; 1997; 124(5):390-2. PubMed ID: 9739896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral characteristics of Prader-Willi syndrome in Korea: comparison with children with mental retardation and normal controls.
    Kim JW; Yoo HJ; Cho SC; Hong KE; Kim BN
    J Child Neurol; 2005 Feb; 20(2):134-8. PubMed ID: 15794180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mazindol (Teronac)- another anorectic drug.
    Drug Ther Bull; 1974 Dec; 12(26):101-2. PubMed ID: 4459058
    [No Abstract]   [Full Text] [Related]  

  • 20. Duplication or insertion in 15q11-13 associated with mental retardation-short stature and obesity-Prader-Willi or Cohen syndrome?
    Fuhrmann-Rieger A; Köhler A; Fuhrmann W
    Clin Genet; 1984 Apr; 25(4):347-52. PubMed ID: 6713711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.